Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Sunshine Biopharma (SBFM) Net Margin (2018 - 2025)

Sunshine Biopharma (SBFM) has disclosed Net Margin for 8 consecutive years, with 3.14% as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Net Margin rose 1734.0% year-over-year to 3.14%, compared with a TTM value of 16.06% through Sep 2025, up 66.0%, and an annual FY2024 reading of 14.72%, up 398.0% over the prior year.
  • Net Margin was 3.14% for Q3 2025 at Sunshine Biopharma, up from 31.36% in the prior quarter.
  • Across five years, Net Margin topped out at 783.75% in Q4 2021 and bottomed at 15440.43% in Q1 2021.
  • Average Net Margin over 5 years is 1651.22%, with a median of 22.49% recorded in 2024.
  • Peak annual rise in Net Margin hit 1443245bps in 2022, while the deepest fall reached -138054bps in 2022.
  • Year by year, Net Margin stood at 783.75% in 2021, then tumbled by -176bps to 596.78% in 2022, then skyrocketed by 97bps to 16.28% in 2023, then plummeted by -38bps to 22.49% in 2024, then soared by 114bps to 3.14% in 2025.
  • Business Quant data shows Net Margin for SBFM at 3.14% in Q3 2025, 31.36% in Q2 2025, and 13.25% in Q1 2025.